Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2024 and 2023 (Expressed in Canadian Dollars) 1 | P a g e June 30, September 30, | --- | --- | --- | --- | |---------------------------------|-------|------------------|----------------| | As at | Notes | 2024 (unaudited) | 2023 (audited) | | | | $ | $ | | ASSETS | | | | | Current Assets | | | | | Cash and cash equivalents | 8 | 6,190,244 | 6,747,986 | | Sales tax receivable | | 17,236 | 36,9 ...

To report suspected adverse reactions, contact Harmony Biosciences at 1-800-833-7460 or the FDA at 1-800- FDA-1088 or www.fda.gov/medwatch. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX. These statements are neither promises nor guar ...

"Following the FDA's decision to grant priority review, we are very pleased with the Agency's timely review and approval of WAKIX for pediatric narcolepsy patients with excessive daytime sleepiness," said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "EDS is the primary symptom experienced by all patients with narcolepsy and this approval for WAKIX, as the first-and-only FDA-approved non-scheduled treatment option for narcolepsy, makes this important treatment option ...

Title: TGFB2 therapeutic for the treatment of CRC, GBM, and PDAC Abstract: OT-101, an antisense against TGFB2, is being tested in phase 3 clinical trials for pancreatic cancer and glioblastoma. It was previously reported to have robust clinical activity in those indications as well as in melanoma. Here, we explore the potential application of OT-101 in colorectal cancer (CRC) through the analysis of CRC patients treated with OT-101 during its clinical development, as well as through bioinformatic. Intraveno ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2024 and 2023 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) | | | March 31, | September 30, | | --- | --- | --- | --- | | | | 2024 | 2023 | | As at | Notes | (unaudited) | (audited) | | | | $ | $ | | ASSETS | | | | | Current Assets | | | | | Cash and cash equivalents | 8 | 5,932,436 ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2023 and 2022 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) | | | December 31, | September 30, | | --- | --- | --- | --- | | | | 2023 | 2023 | | As at | Notes | (unaudited) | (audited) | | | | $ | $ | | ASSETS | | | | | Current Assets | | | | | Cash and cash equivalent ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR For the transition period from _______________ to _______________ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of Registrant specified ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) | | | June 30, | September 30, | | --- | --- | --- | --- | | | | 2023 | 2022 | | As at | Notes | (unaudited) | (audited) | | | | $ | $ | | ASSETS | | | | | Current Assets | | | | | Cash and cash equivalen ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2022 and 2021 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position The accompanying notes are an integral part of these condensed interim consolidated financial statements. 2 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Comprehensive Loss (Expressed in Canadian dollars - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Shares DRUG The Nasdaq Stock Market LLC FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...